Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of Age

Thyroid

Volumn 25, Issue 12, 2015, Pages 1355-1362

  Patel, Dhaval ^a   Kitahara, Cari M ^b   Park, Yikyung ^b,c   Liao, Linda M ^b   Linet, Martha ^b   Kebebew, Electron ^a   Nilubol, Naris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FENOPROFEN; FENOPROFEN CALCIUM; IBUPROFEN; INDOMETACIN; KETOPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; DRUG USE; ETHNICITY; FEMALE; HAZARD RATIO; HUMAN; MALE; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SMOKING; THYROID CANCER; ADULT; AGED; DRINKING BEHAVIOR; META ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTECTION; RISK FACTOR; THYROID NEOPLASMS;

ADULT; AGED; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RISK FACTORS; SEX FACTORS; SMOKING; THYROID NEOPLASMS;

EID: 84951987413     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0198     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ 2006 Cancer statistics, 2006. CA Cancer J Clin 56:106-130.
2. Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, Gazelle GS, Weinstein MC 2014 Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer 120:1345-1352.
3. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT 2000 COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645.
4. Huang M, Chen Q, Xiao J, Liu C, Zhao X 2013 Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer 132:363-373.
5. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM 2007 Increased incidence of welldifferentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204:764-773; discussion 773-765.
6. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR 1995 Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 76: 2312-2318.
7. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL 2002 Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 112:238-242.
8. Krawczyk-Rusiecka K, Lewinski A 2010 Cyclooxygenase-2 expression and its association with thyroid lesions. Arch Med Sci 6:653-657.
9. Lo CY, Lam KY, Leung PP, Luk JM 2005 High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol 152:545-550.
10. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ 3rd 2002 Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 87:358-363.
11. Ji B, Liu Y, Zhang P, Wang Y, Wang G 2012 COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int J Med Sci 9:237-242.
12. Siironen P, Ristimaki A, Nordling S, Louhimo J, Haapiainen R, Haglund C 2004 Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 44: 490-497.
13. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV 2005 Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 18:221-227.
14. Scarpino S, Duranti E, Stoppacciaro A, Pilozzi E, Natoli G, Sciacchitano S, Luciani E, Ruco L 2009 COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. J Pathol 218:487-494.
15. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ 2000 Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60:5767-5772.
16. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS 2005 Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914-923.
17. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M 2009 Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501-507.
18. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, Freedman LS, Brown CC, Midthune D, Kipnis V 2001 Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154: 1119-1125.
19. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK 2000 Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21:273S-309S.
20. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, Caporaso N, Ziegler RG, Johnson CC, Weissfeld JL, Hoover RN, Hartge P, Palace C, Gohagan JK 2000 Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21:349S-355S.
21. Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, Hauptmann M, Mohan AK, Yoshinaga S, Hill DA, Tarone R, Mabuchi K, Ron E, Linet MS 2003 Cancer incidence in the US radiologic technologists health study, 1983-1998. Cancer 97:3080-3089.
22. Boice JD Jr, Mandel JS, Doody MM, Yoder RC, McGowan R 1992A health survey of radiologic technologists. Cancer 69:586-598.
23. Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, Schatzkin A, Hollenbeck AR, Silverman DT 2011 Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 173:721-730.
24. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J 2006 Assessing heterogeneity in meta-analysis: Q statistic or I2 index Psychol Methods 11:193-206.
25. DerSimonian R, Laird N 1986 Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
26. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A 2003 Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 42:492-497.
27. Menter DG, Schilsky RL, DuBois RN 2010 Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16:1384-1390.
28. Wang D, Dubois RN 2010 The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788.
29. Udelsman R, Zhang Y 2014 The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid 24:472-479.
30. Morris LG, Sikora AG, Tosteson TD, Davies L 2013 The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23:885-891.
31. Arterburn DE, Maciejewski ML, Tsevat J 2005 Impact of morbid obesity on medical expenditures in adults. Int J Obes (Lond) 29:334-339.
32. Zabel EW, Alexander BH, Mongin SJ, Doody MM, Sigurdson AJ, Linet MS, Freedman DM, Hauptmann M, Mabuchi K, Ron E 2006 Thyroid cancer and employment as a radiologic technologist. Int J Cancer 119: 1940-1945.